LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 374

Search options

  1. Article: The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies.

    Asano, Yoshihide

    Journal of clinical medicine

    2020  Volume 9, Issue 9

    Abstract: Systemic sclerosis (SSc) is a multisystem autoimmune and vascular disease resulting in fibrosis of various organs with unknown etiology. Accumulating evidence suggests that a common pathologic cascade across multiple organs and additional organ-specific ... ...

    Abstract Systemic sclerosis (SSc) is a multisystem autoimmune and vascular disease resulting in fibrosis of various organs with unknown etiology. Accumulating evidence suggests that a common pathologic cascade across multiple organs and additional organ-specific pathologies underpin SSc development. The common pathologic cascade starts with vascular injury due to autoimmune attacks and unknown environmental factors. After that, dysregulated angiogenesis and defective vasculogenesis promote vascular structural abnormalities, such as capillary loss and arteriolar stenosis, while aberrantly activated endothelial cells facilitate the infiltration of circulating immune cells into perivascular areas of various organs. Arteriolar stenosis directly causes pulmonary arterial hypertension, scleroderma renal crisis and digital ulcers. Chronic inflammation persistently activates interstitial fibroblasts, leading to the irreversible fibrosis of multiple organs. The common pathologic cascade interacts with a variety of modifying factors in each organ, such as keratinocytes and adipocytes in the skin, esophageal stratified squamous epithelia and myenteric nerve system in gastrointestinal tract, vasospasm of arterioles in the heart and kidney, and microaspiration of gastric content in the lung. To better understand SSc pathogenesis and develop new disease-modifying therapies, it is quite important to understand the complex pathogenesis of SSc from the two distinct perspectives, namely the common pathologic cascade and additional organ-specific pathologies.
    Language English
    Publishing date 2020-08-19
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm9092687
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Biologics for Reducing Cardiovascular Risk in Psoriasis Patients.

    Terui, Hitoshi / Asano, Yoshihide

    Journal of clinical medicine

    2023  Volume 12, Issue 3

    Abstract: Psoriasis is a chronic inflammatory skin disease with a high prevalence of cardiovascular disease (CVD), obesity, dyslipidemia, hypertension, diabetes mellitus, and metabolic syndrome. Among them, CVD is the most common cause of morbidity and mortality ... ...

    Abstract Psoriasis is a chronic inflammatory skin disease with a high prevalence of cardiovascular disease (CVD), obesity, dyslipidemia, hypertension, diabetes mellitus, and metabolic syndrome. Among them, CVD is the most common cause of morbidity and mortality in psoriasis patients. Since CVD is associated with considerable morbidity and mortality, primary care clinicians are increasingly committed to reducing the risk of CVD in patients with psoriasis. Biologics targeting TNF-α, IL-12/23, and IL-17 are systemic therapies that can dramatically improve the condition of psoriasis. Recent studies have reported that these inflammatory cytokine signals may promote atherosclerosis, suggesting that biologics might be effective for improving psoriasis as well as reducing the risk of CVD. Here, we reviewed cardiovascular risk in psoriasis patients, the association between psoriatic inflammation and atherosclerosis, and the efficacy of biologics for reducing the risk of cardiovascular diseases.
    Language English
    Publishing date 2023-02-01
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm12031162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Eosinophilic annular erythema successfully treated with dupilumab: A case report.

    Okazaki, Toshiki / Takahashi, Takehiro / Asano, Yoshihide

    The Journal of dermatology

    2024  

    Language English
    Publishing date 2024-02-17
    Publishing country England
    Document type Letter
    ZDB-ID 800103-0
    ISSN 1346-8138 ; 0385-2407
    ISSN (online) 1346-8138
    ISSN 0385-2407
    DOI 10.1111/1346-8138.17158
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: COVID-19 vaccination-induced Sweet syndrome in a patient with squamous cell carcinoma treated with nivolumab.

    Takahashi, Takuya / Fujimura, Taku / Terui, Hitoshi / Asano, Yoshihide

    European journal of dermatology : EJD

    2024  Volume 34, Issue 1, Page(s) 98–100

    MeSH term(s) Humans ; Carcinoma, Squamous Cell/drug therapy ; COVID-19 ; COVID-19 Vaccines/adverse effects ; Head and Neck Neoplasms ; Neoplasm Recurrence, Local ; Nivolumab/therapeutic use ; Sweet Syndrome/chemically induced
    Chemical Substances COVID-19 Vaccines ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2024-04-01
    Publishing country France
    Document type Case Reports ; Journal Article
    ZDB-ID 1128666-0
    ISSN 1952-4013 ; 1167-1122
    ISSN (online) 1952-4013
    ISSN 1167-1122
    DOI 10.1684/ejd.2024.4604
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: What can we learn from

    Asano, Yoshihide

    Journal of scleroderma and related disorders

    2018  Volume 3, Issue 1, Page(s) 6–13

    Abstract: Systemic sclerosis is a complex multifactorial disease characterized by autoimmunity, vasculopathy, and selective organ fibrosis. A series of genetic and epidemiological studies have demonstrated that environmental influences play a central role in the ... ...

    Abstract Systemic sclerosis is a complex multifactorial disease characterized by autoimmunity, vasculopathy, and selective organ fibrosis. A series of genetic and epidemiological studies have demonstrated that environmental influences play a central role in the onset of systemic sclerosis, while genetic factors determine the susceptibility to and the severity of this disease. Therefore, the identification of predisposing factors related to environmental influences would provide us with an informative clue to better understand the pathological process of this disease. Based on this concept, the deficiency of transcription factor Friend leukemia virus integration 1, which is epigenetically suppressed in systemic sclerosis, seems to be a potential candidate acting as the predisposing factor of this disease. Indeed,
    Language English
    Publishing date 2018-04-04
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2397-1991
    ISSN (online) 2397-1991
    DOI 10.1177/2397198318758221
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Eruptive milium-like syringoma: A case report.

    Takahashi, Takuya / Fujimura, Taku / Asano, Yoshihide

    The Journal of dermatology

    2023  Volume 50, Issue 11, Page(s) e377–e378

    MeSH term(s) Humans ; Syringoma/diagnosis ; Sweat Gland Neoplasms/diagnosis ; Sweat Gland Neoplasms/surgery ; Epidermal Cyst ; Exanthema
    Language English
    Publishing date 2023-07-06
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 800103-0
    ISSN 1346-8138 ; 0385-2407
    ISSN (online) 1346-8138
    ISSN 0385-2407
    DOI 10.1111/1346-8138.16887
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer.

    Sekine, Mana / Terui, Hitoshi / Fujimura, Taku / Asano, Yoshihide

    Case reports in oncology

    2023  Volume 16, Issue 1, Page(s) 419–421

    Abstract: Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor. Since olaparib is a newly approved drug, there ... ...

    Abstract Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor. Since olaparib is a newly approved drug, there are few reports of skin disorders that may be triggered by olaparib administration. In this report, we present a case with an olaparib-induced drug eruption presenting multiple purpuras on the patient's fingers and fingertips. The present case suggests that olaparib might induce purpura as nonallergic drug eruption.
    Language English
    Publishing date 2023-06-02
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2458961-5
    ISSN 1662-6575
    ISSN 1662-6575
    DOI 10.1159/000530981
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Recent advances in the treatment of skin involvement in systemic sclerosis.

    Asano, Yoshihide

    Inflammation and regeneration

    2017  Volume 37, Page(s) 12

    Abstract: Skin fibrosis is a devastating clinical condition commonly seen in skin-restricted and systemic disorders. The goal of skin fibrosis treatment is the restoration of abnormally activated dermal fibroblasts producing the excessive amount of extracellular ... ...

    Abstract Skin fibrosis is a devastating clinical condition commonly seen in skin-restricted and systemic disorders. The goal of skin fibrosis treatment is the restoration of abnormally activated dermal fibroblasts producing the excessive amount of extracellular matrix, which is generally a final consequence of the complex disease process including the activation of vascular and immune systems. Among various skin fibrotic conditions, the molecular mechanisms underlying dermal fibroblast activation have been mostly well studied in systemic sclerosis (SSc). SSc is a multisystem autoimmune and vascular disease resulting in extensive fibrosis of the skin and various internal organs. Since SSc pathogenesis is believed to include all the critical components regulating tissue fibrosis, the studies on anti-fibrotic drugs against SSc provide us much useful information regarding the strategy for the treatment of various skin fibrotic conditions. In the recent decade, as is the case with other autoimmune and inflammatory diseases, the molecular targeting therapy with monoclonal antibody has been clinically well examined in SSc. Promising clinical outcomes are so far reported in tocilizumab (an anti-IL-6 receptor antibody), rituximab (an anti-CD20 antibody), and fresolimumab (an anti-TGF-β antibody). The analysis of gene expression profiles in skin lesions of SSc patients treated with tocilizumab or fresolimumab revealed a critical role of monocyte-macrophage lineage cells in the development of skin fibrosis and the involvement of IL-6 and TGF-β in the activation of those cells. Considering that B cells modulate the differentiation and activation of macrophages, favorable clinical outcomes of rituximab treatment imply the central role of B cell/monocyte-macrophage lineage cell axis in the pathogenesis of SSc. This scenario may be applicable at least partly to other skin fibrotic conditions. In this review article, the currently available data on these drugs are summarized and the future directions are discussed.
    Language English
    Publishing date 2017-06-12
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2051471-2
    ISSN 1880-9693 ; 0389-4290
    ISSN 1880-9693 ; 0389-4290
    DOI 10.1186/s41232-017-0047-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Targeting B cells for treatment of systemic sclerosis.

    Terui, Hitoshi / Segawa, Yuichiro / Asano, Yoshihide

    Current opinion in rheumatology

    2023  Volume 35, Issue 6, Page(s) 317–323

    Abstract: Purpose of review: The pathogenesis of systemic sclerosis (SSc) has been linked to dysfunctional B cells as demonstrated in previous research. This review aims to show the evidence and ongoing clinical trials of B cell-targeted therapy and overview the ... ...

    Abstract Purpose of review: The pathogenesis of systemic sclerosis (SSc) has been linked to dysfunctional B cells as demonstrated in previous research. This review aims to show the evidence and ongoing clinical trials of B cell-targeted therapy and overview the various aspects of B cell involvement in SSc.
    Recent findings: We provide an overview of the current understanding and therapeutic strategies targeting B cells in SSc patients. Several molecular targets of B cells have been identified for treating SSc, including CD20, CD19, B-cell activating factor (BAFF), and proteasome.
    Summary: Many clinical trials have demonstrated that B cells play a critical role in the pathogenesis of SSc and may be a potential therapeutic target to improve disease symptoms. Although large-scale clinical studies are needed, various B cell-targeted therapies have the potential to address the unmet needs of SSc patients.
    MeSH term(s) Humans ; Scleroderma, Systemic/pathology ; B-Lymphocytes ; Longitudinal Studies
    Language English
    Publishing date 2023-08-03
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1045317-9
    ISSN 1531-6963 ; 1040-8711
    ISSN (online) 1531-6963
    ISSN 1040-8711
    DOI 10.1097/BOR.0000000000000961
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Systemic sclerosis.

    Asano, Yoshihide

    The Journal of dermatology

    2017  Volume 45, Issue 2, Page(s) 128–138

    Abstract: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by vasculopathy and tissue fibrosis of the skin and various internal organs. A series of genetic and epidemiological studies have demonstrated that SSc onset is determined by the ... ...

    Abstract Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by vasculopathy and tissue fibrosis of the skin and various internal organs. A series of genetic and epidemiological studies have demonstrated that SSc onset is determined by the accumulation of predisposing factors related to environmental influences, while genetic factors affect the susceptibility to and the severity of this disease. This notion has been confirmed by recent advance in animal models. The initial trigger of SSc is believed to be autoimmune attacks to endothelial cells, which occur in individuals with the genetic susceptibility to autoimmune diseases and/or the cumulative exposure to certain SSc-related environmental influences. Then, endothelial cells are aberrantly activated or damaged, leading to the development of vascular structural changes, such as destructive vasculopathy and proliferative obliterative vasculopathy, and tissue fibrosis. In parallel, inflammatory cells activate SSc fibroblasts and modify the metabolism of extracellular matrix by soluble factors and autoantibodies. Prior to or during these processes, SSc fibroblasts acquire the ability to selectively respond to profibrotic growth factors and cytokines, persistently producing excessive amount of extracellular matrix. SSc fibroblasts also modify immune responses, at least those of CD4
    MeSH term(s) Autoantibodies/immunology ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/genetics ; Autoimmune Diseases/immunology ; Autoimmune Diseases/pathology ; Autoimmunity/genetics ; Autoimmunity/immunology ; CD4-Positive T-Lymphocytes/immunology ; Endothelial Cells/immunology ; Fibroblasts/immunology ; Fibrosis ; Genetic Predisposition to Disease ; Humans ; Immunologic Factors/therapeutic use ; Macrophages/immunology ; Scleroderma, Systemic/drug therapy ; Scleroderma, Systemic/genetics ; Scleroderma, Systemic/immunology ; Scleroderma, Systemic/pathology ; Skin/blood supply ; Skin/cytology ; Skin/immunology ; Skin/pathology ; Vascular Remodeling/immunology
    Chemical Substances Autoantibodies ; Immunologic Factors
    Language English
    Publishing date 2017-12-10
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 800103-0
    ISSN 1346-8138 ; 0385-2407
    ISSN (online) 1346-8138
    ISSN 0385-2407
    DOI 10.1111/1346-8138.14153
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top